Impact of anti-inflammatory treatment on the onset of XXXX in juvenile idiopathic arthritis: Longitudinal analysis from a nation-wide paediatric rheumatological database.

@entity1 @entity66 @entity625 @entity6822 @entity1596 @entity2874 @entity1499
PURPOSE: Based on a nation-wide database, this study analysed the influence of @entity1499 ( @entity6822 ), @entity2874 inhibitors and a combination of the two on @entity1596 occurrence in JIA @entity1 . METHODS: Data from the National Paediatric Rheumatological Database in Germany were used in this study. Between 2002 and 2013, data from JIA @entity1 were annually documented at the participating paediatric rheumatological sites. @entity1 with @entity66 duration of less than 12 months at initial documentation and >= 2 years of follow-up were included in this study. The impact of anti-inflammatory treatment on the occurrence of @entity1596 was evaluated by discrete-time survival analysis. RESULTS: A total of 3,512 JIA @entity1 (mean age 8.3  4.8 years, female 65.7%, ANA-positive 53.2%, mean age at @entity625 onset 7.8  4.8 years) fulfilled the inclusion criteria. Mean total follow-up time was 3.6  2.4 years. @entity1596 developed in a total of 180 @entity1 (5.1%) within one year after @entity625 onset. @entity1596 onset after the first year was observed in another 251 @entity1 (7.1%). DMARD treatment in the year before @entity1596 onset significantly reduced the risk for @entity1596 : @entity6822 (HR 0.63, p=0.022), @entity2874 inhibitors (HR 0.56, p<0.001) and a combination of the two (HR 0.10, p<0.001). @entity1 treated with @entity6822 within the first year of JIA had an even a lower @entity1596 risk (HR 0.29, p<0.001). CONCLUSION: The use of DMARDs in JIA @entity1 significantly reduced the risk for @entity1596 onset. Early @entity6822 use within the first year of disease and the combination of @entity6822 with a @entity2874 inhibitor had the highest protective effect. This article is protected by copyright. All rights reserved.
